MediPurpose to Showcase the Anzen Safety Scalpel at Clinical Congress 2018

September 21, 2018

MediPurpose seeks surgeon champion to test new metal-handle safety scalpel

Duluth, Georgia – MediPurpose, a medical products company specializing in sharps safety devices, announced today that it will participate in the American College of Surgeons (ACS) Clinical Congress 2018 in Boston, MA from Oct 21 – 25, 2018.

Clinical Congress 2018 features outstanding education and training opportunities for surgeons, residents, medical students, and surgical team members. Attendees will find cutting-edge surgical research, hands-on-learning opportunities, timely discourse on the most relevant surgical topics and unparalleled peer access.

MediPurpose encourages all attendees to stop by booth #1106 to provide feedback on sharps safety and safety scalpels. MediPurpose is also looking for surgeons passionate about sharps safety to be the champion at their facility and lead product evaluations. All exhibit attendees that fill out a survey form stand a chance to win an Apple Watch.

“MediPurpose is currently beta testing our Anzen Safety Scalpel. Clinical Congress 2017 is a great opportunity to connect with end-users and understand theirs concerns and needs regarding their ideal safety scalpel,” said Patrick Yi, CEO and founder of MediPurpose.


About MediPurpose

MediPurpose, founded in 1999, develops, manufactures, and distributes superior sharps safety devices including the Anzen safety scalpel, SurgiLance safety lancets and MediPlus wound care products. MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and medical product distributors.

MediPurpose’s Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical products markets. For more information, visit

Media Contact:
[email protected]